San Francisco, CA, United States of America

Youjin Lee

USPTO Granted Patents = 2 

Average Co-Inventor Count = 8.0

ph-index = 1


Location History:

  • San Francisco, CA (US) (2021)
  • Boston, MA (US) (2022)

Company Filing History:


Years Active: 2021-2022

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Youjin Lee

Introduction

Youjin Lee is a prominent inventor based in San Francisco, CA, known for her significant contributions to the field of immunology. With a focus on T cell balance and gene expression, she has developed innovative methods and compositions that have the potential to impact therapeutic and diagnostic applications.

Latest Patents

Youjin Lee holds two patents, both centered around the theme of T cell balance gene expression. Her latest invention relates to compositions and methods for identifying the regulatory network that modulates, controls, or influences T cell balance, particularly in the differentiation, maintenance, and function of Th17 cells. This invention aims to exploit the regulatory network for various therapeutic and diagnostic indications. Additionally, it involves identifying and utilizing target genes and gene products that influence T cell balance.

Career Highlights

Throughout her career, Youjin Lee has worked with esteemed institutions such as the Broad Institute, Inc. and the Massachusetts Institute of Technology. Her work has been instrumental in advancing the understanding of T cell biology and its implications for health and disease.

Collaborations

Youjin has collaborated with notable scientists in her field, including Aviv Regev and Vijay K. Kuchroo. These collaborations have further enriched her research and contributed to the development of innovative solutions in immunology.

Conclusion

Youjin Lee's work exemplifies the intersection of innovation and science, particularly in the realm of immunology. Her patents and collaborations highlight her commitment to advancing our understanding of T cell balance and its therapeutic potential.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…